Company details are restricted to VIN members. Become a member to view company details.
OsteoVantage™ is developing bioelectric stimulation technology that is targeted at transforming spine and orthopedics treatments with its proprietary INDOS™ (Induced Osteogenic Stimulation) technology platform. INDOS™ integrates modern implant design and direct current electrical stimulation to create a new and highly differentiated class of bioelectric stimulation fixation hardware. These new implants provide full implant function while also delivering Osteomodulation™ therapy to improve bone graft fusion, bone healing, implant osseointegration and potentially reduce pain. INDOS™ implants could serve market segments representing approximately 70% of the spine, orthopedic and orthodontic markets. The company’s initial focus with animal studies has been for spinal fusion.
The Problem: Surgeons treat an array of common conditions associated with spinal degeneration. Bone fusion (“fusion”) is used to achieve and maintain long-term spinal alignment and stabilization. Fusion failure (“pseudarthrosis” or “non-union”) occurs when the intended bone graft incorporation does not occur, and spinal alignment and stability are not adequately maintained. Patients failing to fuse are clinical failures and commonly endure chronic pain, reduced productivity, disability, costly continued care, damaged or broken implants and expensive repeat surgery. Cumulative reoperation rate for lumbar spine fusion surgery are reported to be close to 20% during the decade following the initial procedure. There is a compelling medical need for improved spinal fusion technology.
The Solution: OsteoVantage’s INDOS technology integrates spine implants with direct current electrical stimulation to improve fusion results. This is achieved with fixation hardware that is capable of generating and targeting therapeutic electrical stimuli in the injury site. The proprietary design of selectively anodized bone screws is the technology’s critical element. OsteoVantage is first using INDOS to produce osteomodulating pedicle screw systems and then subsequently deploy it to other products and clinical fields. Results in animal trials to date show substantially improved and faster fusion.
Market Opportunity: Spine is the initial target market for INDOS with trauma, joint replacement and dental as other identified opportunities. The worldwide orthopedic market was estimated to be over $40B in 2016 and growing at a 4.4% compound annual growth rate. Spine represented approximately $9B in 2016. An increasingly aged population, the emerging “echo-boomer” healthcare consumer and expanding emerging market affluence and infrastructure drive outstanding global volume growth. The global spine market is an oligopoly with the top three competitors holding a 66% share of the market. However, the spine market is notable because innovative and responsive smaller competitors successfully compete and often grow at much faster rates than larger competitors and the overall market (ex. NuVasive, Globus, K2M, LDR, others). The spine market has historically rewarded fast moving and innovative upstarts.